Further, a consensus statement from the Melanoma Nursing Initiative on managing adverse events offers a positive, comprehensive nursing approach that gives clinicians resources to guide clinical care for patients who develop irAEs while receiving anti-PD-1/PD-L1 therapy [68]. The gene discussed is PDCD1; the disease is melanoma.